24475-36-3

Usage

InChI:InChI=1/C14H20O2/c1-14(2,3)12-9-7-11(8-10-12)5-4-6-13(15)16/h7-10H,4-6H2,1-3H3,(H,15,16)

Upstream product

• 996-82-7 sodium diethylmalonate 
• 56829-61-9 1-(2-bromoethyl)-4-(tert-butyl)benzene 
• 35288-08-5 4-(4-tert-butylphenyl)-4-oxobutyric acid 
• 253185-03-4 tert-butylbenzene 
• 54338-32-8 4-(4-cyclohexylphenyl)butanoic Acid 
• 108-30-5 succinic acid anhydride 
• 27798-45-4 1-allyl-4-(tert-butyl)benzene 

Downstream Products

• 134030-39-0 ethyl 4-(4-(tert-butyl)phenyl)butanoate 
• 855220-19-8 4-(4-tert-butyl-phenyl)-butyryl chloride 
• 18127-01-0 3-(4-tert-butylphenyl)propionaldehyde 
• 78574-08-0 3-(4-tert-butylphenyl)propan-1-ol 
• 127897-29-4 9-[3-(4-tert-Butyl-phenyl)-propyl]-acridine 
• 58567-80-9 1-(tert-butyl)-4-propylbenzene 
• 4838-42-0 9,10,9',10'-tetrahydro-9,9'-biacridyl 
• 22583-68-2 7-(1,1-dimethylethyl)-3,4-dihydro-1(2H)-naphthalenone 
• 124694-03-7 1-(4-bromobutyl)-4-(tert-butyl)benzene 
• 1221819-66-4 4-(4-tert-butylphenyl)-N,N-dimethylbutanamide 
• 72768-33-3 1-[1,7-bis-(4-t-butylphenyl)-4-heptyl]-1,5,9,13-tetrazatridecane 
• 72781-46-5 1-[1,7-di-(4-t-butylphenyl)-4-heptyl]-1,4,7,10-tetrazadecane 
• 72781-44-3 [3-(3-Amino-propylamino)-propyl]-{4-(4-tert-butyl-phenyl)-1-[3-(4-tert-butyl-phenyl)-propyl]-butyl}-amine 
• 84029-99-2 1,1-Dimethyl-7-t-butylnaphthalene 

Relevant academic research and scientific papers

Carbonylative Transformation of Allylarenes with CO Surrogates: Tunable Synthesis of 4-Arylbutanoic Acids, 2-Arylbutanoic Acids, and 4-Arylbutanals

In this Communication, procedures for the selective synthesis of 4-arylbutanoic acids, 2-arylbutanoic acids, and 4-arylbutanals from the same allylbenzenes have been developed. With formic acid or TFBen as the CO surrogate, reactions proceed selectively and effectively under carbon monoxide gas-free conditions.

DOUBLE-ACYLATED GLP-1 DERIVATIVES

The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1 (7-37), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: ????????Chem. 1:?????HOOC-(CH2)x-CO-* ????????Chem. 2:?????HOOC-C6H4-O-(CH2)y-CO-* ????????Chem. 3:?????R1-C6H4-(CH2)z-CO-* ????????Chem. 4:?????HOOC-C4SH2-(CH2)w-CO-* in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, R1 is a group having a molar mass not higher than 150 Da, and w is an integer in the range of 6-18; with the proviso that when the protracting moiety is Chem. 1, the albumin binding moiety further comprises a linker of formula Chem. 5: *-NH-(CH2)2-(O-(CH2)2)k-O-(CH2)n-CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.

SYNTHESIS OF SUBSTITUTED TETRAHYDROINDENYL COMPLEXES

This invention relates to the synthesis of substituted tetrahydroindenyls and the use of the synthesised complexes in the homo- and co-polymerisation of ethylene and alpha-olefins.

Oxetanes in drug discovery: Structural and synthetic insights

An oxetane can trigger profound changes in aqueous solubility, lipophilicity, metabolic stability, and conformational preference when replacing commonly employed functionalities such as gem-dimethyl or carbonyl groups. The magnitude of these changes depends on the structural context. Thus, by substitution of a gem-dimethyl group with an oxetane, aqueous solubility may increase by a factor of 4 to more than 4000 while reducing the rate of metabolic degradation in most cases. The incorporation of an oxetane into an aliphatic chain can cause conformational changes favoring synclinal rather than antiplanar arrangements of the chain. Additionally spirocyclic oxetanes (e.g., 2-oxa-6-aza-spiro[3.3]heptane) bear remarkable analogies to commonly used fragments in drug discovery, such as morpholine, and are even able to supplant the latter in its solubilizing ability. A rich chemistry of oxetan-3-one and derived Michael acceptors provide venues for the preparation of a broad variety of novel oxetanes not previously documented, thus providing the foundation for their broad use in chemistry and drug discovery.

AMINO ALCOHOL COMPOUND

A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): (wherein R 1 represents a methyl group or an ethyl group, R 2 represents a methyl group or an ethyl group, and R 3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

Phosphonic acid compounds, their production and use

The present invention relates to a compound of the general formula (I): STR1 wherein ring A is a benzene ring that may be substituted; Y is a divalent group as a constituent member of ring B forming a 5- to 8-membered ring; Q1 is a group of the formula --X--P(O)(OR1)(OR2) wherein X is a bond or a divalent group; R1 and R2, identical or different, are hydrogen or a lower alkyl, or may be combined together to form a ring; Q2 is hydrogen, a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; and the group of the formula --CON(Q1)(Q2) is connected to the a- or b-position carbon atom, or a salt thereof, which is useful as prophylactic and therapeutic agents of various metabolic bone diseases such as osteoporosis.

Electron Paramagnetic Resonance Spectra of Substituted 1- and 2-Naphthylmethyl Radicals

The EPR spectra of 7-tert-butyl-1-naphthylmethyl and 6-tert-butyl-2-naphthylmethyl radicals, prepared by photolysis of the hydrocarbon with tert-butyl peroxide at -40 deg C, have been analysed by correlation methods: average α(C-H) coupling constants are 15.0 and 15.25 G respectively, in line with the expected relative stabilities of the two radicals and the recently reported stabilization energy for 1-naphthylmethyl.

Antihistamines

N-(Arylalkyl) dibenzoxepin propanamines useful as antihistamines, such as 3-dibenz[b,e]oxepin-11(6H)-ylidene-N-methyl-N-[6-[4-(1,1-dimethylethyl)phenyl]-6-oxohexyl]-1-propanamine hydrochloride.